Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.30 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CFTR | P13569 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23905423 | 1.00 | GRM2 (0.31) | GRM2KCNH2NR1I2SCN9ACYP3A4 | |
| SCHEMBL23196145 | 0.88 | CNR2 (0.32) | KCNH2 | |
| SCHEMBL23905511 | 0.88 | CFTR (0.31) | CFTR | |
| SCHEMBL23905937 | 0.88 | GABRA5 (0.33) | GRM2KCNH2CYP3A4CFTR | |
| SCHEMBL23905800 | 0.87 | PTGS1 (0.31) | — | |
| SCHEMBL24363612 | 0.87 | PTGS1 (0.31) | — | |
| SCHEMBL23196033 | 0.85 | GRM2 (0.37) | GRM2SCN9ACFTR | |
| SCHEMBL23195908 | 0.85 | MAPK14 (0.36) | KDM4EALDH1A1 | |
| SCHEMBL23904779 | 0.82 | ADORA2A (0.31) | — | |
| SCHEMBL23904889 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021198981-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | Janssen Biopharma, Inc. (US) | 2021-10-07 | — | — | WO | disclosed |